Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$19.01 – $25.69
53% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.27B | $1.95B | $1.64B | $1.59B | $1.76B | $1.28B | $2.36B |
| Cost of revenue | $369.4M | $427.9M | $725.6M | $629.0M | $642.7M | $698.4M | $750.1M | $846.7M |
| Gross profit | $747.4M | $845.5M | $1.22B | $1.01B | $945.9M | $1.06B | $530.2M | $1.52B |
| Gross margin | 66.9% | 66.4% | 62.8% | 61.7% | 59.5% | 60.3% | 41.4% | 64.2% |
| R&D | $104.6M | $118.5M | $136.7M | $154.0M | $174.3M | $198.2M | $226.9M | $237.9M |
| Operating income | $351.7M | $374.4M | $723.2M | $509.1M | $334.7M | $254.4M | −$371.0M | $673.7M |
| EBITDA | $351.7M | $435.4M | $808.2M | $605.1M | $433.7M | $368.2M | $654.3M | $833.9M |
| Net income | $217.9M | $287.3M | $524.2M | $376.9M | $250.3M | $132.6M | $377.2M | $473.2M |
| Net margin | 19.5% | 22.6% | 26.9% | 22.9% | 15.8% | 7.5% | 29.5% | 20.0% |
| EPS (diluted) | 0.38 | 0.50 | 0.91 | 0.65 | 0.43 | 0.23 | 0.64 | 0.81 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $1.4B | $0.52 | $0.50–$0.54 | 1 |
| 2028 | $1.6B | $0.61 | $0.58–$0.63 | 1 |
| 2029 | $1.8B | $0.71 | $0.68–$0.73 | 1 |
| 2030 | $1.9B | $0.72 | $0.69–$0.75 | 1 |
Forward consensus · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| FSPKFFisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.2B | — |
| ALBBYAlibaba Health Information Technology Limited | $8.46 | +6.82% | $6.8B | — |
| ALBHFAlibaba Health Information Technology Limited | $0.41 | -1.47% | $6.7B | — |
| BDUUYBangkok Dusit Medical Services Public Company Limited | $23.41 | +0.00% | $9.3B | — |
| CHEOFCochlear Limited |
FISHER & PAYKEL HLTHCRE
No one on the platform currently holds FSPKF.
No tracked institution reports a position in FSPKF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-23 | $0.4583 | 2026-07-03 |
| 2026-06-23 | $0.0582 | 2026-07-03 |
| 2025-12-04 | $0.0335 | 2025-12-16 |
| 2025-12-04 | $0.2639 | 2025-12-16 |
| 2025-06-24 | $0.0424 | 2025-07-04 |
| 2025-06-24 | $0.3333 | 2025-07-04 |
| 2024-12-06 | $0.0326 | 2024-12-18 |
| 2024-12-06 | $0.2569 | 2024-12-18 |
| 2024-06-27 | $0.0415 | 2024-07-10 |
| 2024-06-27 | $0.3264 | 2024-07-10 |
No one on the platform has traded FSPKF yet.
| $81.42 |
| -1.08% |
| $5.3B |
| — |
| CHEOYCochlear Limited | $42.03 | +0.69% | $5.5B | — |
| CHJTFCSPC Pharmaceutical Group Limited | $0.98 | +0.00% | $11.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-05 | $0.2500 | 2023-12-18 |
| 2023-12-05 | $0.0318 | 2023-12-18 |
| Execution date | Ratio |
|---|---|
| 2004-10-04 | 5-for-1 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 34.0× earnings vs its 29.8× historical median P/E.
Fair value ≈ $19.75 · price $22.52 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.